NASDAQ:MYGN

Myriad Genetics Competitors

$27.31
0.00 (0.00 %)
(As of 04/19/2021 02:26 PM ET)
Add
Compare
Today's Range
$26.55
Now: $27.31
$27.39
50-Day Range
$27.46
MA: $29.70
$31.60
52-Week Range
$10.54
Now: $27.31
$33.97
Volume13,968 shs
Average Volume802,747 shs
Market Capitalization$2.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

Myriad Genetics (NASDAQ:MYGN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying MYGN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Myriad Genetics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Myriad Genetics (NASDAQ:MYGN) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

96.7% of Myriad Genetics shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 2.8% of Myriad Genetics shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Myriad Genetics and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myriad Genetics13001.75
Amgen091402.61

Myriad Genetics currently has a consensus price target of $21.00, suggesting a potential downside of 22.02%. Amgen has a consensus price target of $261.1429, suggesting a potential upside of 2.45%. Given Amgen's stronger consensus rating and higher probable upside, analysts plainly believe Amgen is more favorable than Myriad Genetics.

Valuation and Earnings

This table compares Myriad Genetics and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$638.60 million3.22$-199,500,000.00($0.35)-78.03
Amgen$23.36 billion6.31$7.84 billion$14.8217.27

Amgen has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Myriad Genetics and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myriad Genetics-32.49%-4.07%-2.68%
Amgen29.42%95.55%15.52%

Volatility & Risk

Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats Myriad Genetics on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 2.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Gilead Sciences and Myriad Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
Myriad Genetics13001.75

Gilead Sciences currently has a consensus target price of $97.68, suggesting a potential upside of 47.58%. Myriad Genetics has a consensus target price of $21.00, suggesting a potential downside of 22.02%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Gilead Sciences is more favorable than Myriad Genetics.

Earnings & Valuation

This table compares Gilead Sciences and Myriad Genetics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.70$5.39 billion$6.1410.74
Myriad Genetics$638.60 million3.22$-199,500,000.00($0.35)-78.03

Gilead Sciences has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Myriad Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Myriad Genetics-32.49%-4.07%-2.68%

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Gilead Sciences beats Myriad Genetics on 11 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Vertex Pharmaceuticals and Myriad Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Myriad Genetics13001.75

Vertex Pharmaceuticals currently has a consensus target price of $293.2083, suggesting a potential upside of 33.81%. Myriad Genetics has a consensus target price of $21.00, suggesting a potential downside of 22.02%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Myriad Genetics.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Myriad Genetics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.70$1.18 billion$4.2951.36
Myriad Genetics$638.60 million3.22$-199,500,000.00($0.35)-78.03

Vertex Pharmaceuticals has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Myriad Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Myriad Genetics-32.49%-4.07%-2.68%

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Myriad Genetics on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Myriad Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Myriad Genetics13001.75

Regeneron Pharmaceuticals currently has a consensus target price of $644.1739, suggesting a potential upside of 28.63%. Myriad Genetics has a consensus target price of $21.00, suggesting a potential downside of 22.02%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Myriad Genetics.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Myriad Genetics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.86$2.12 billion$21.4723.45
Myriad Genetics$638.60 million3.22$-199,500,000.00($0.35)-78.03

Regeneron Pharmaceuticals has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Myriad Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Myriad Genetics-32.49%-4.07%-2.68%

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Myriad Genetics on 13 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Insider & Institutional Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 2.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Biogen and Myriad Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Myriad Genetics13001.75

Biogen currently has a consensus target price of $303.3103, suggesting a potential upside of 13.68%. Myriad Genetics has a consensus target price of $21.00, suggesting a potential downside of 22.02%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Biogen is more favorable than Myriad Genetics.

Earnings & Valuation

This table compares Biogen and Myriad Genetics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.84$5.89 billion$33.578.00
Myriad Genetics$638.60 million3.22$-199,500,000.00($0.35)-78.03

Biogen has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Myriad Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Myriad Genetics-32.49%-4.07%-2.68%

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Summary

Biogen beats Myriad Genetics on 10 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Alexion Pharmaceuticals and Myriad Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Myriad Genetics-32.49%-4.07%-2.68%

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Myriad Genetics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.31$2.40 billion$9.7416.96
Myriad Genetics$638.60 million3.22$-199,500,000.00($0.35)-78.03

Alexion Pharmaceuticals has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alexion Pharmaceuticals and Myriad Genetics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Myriad Genetics13001.75

Alexion Pharmaceuticals presently has a consensus target price of $153.4286, suggesting a potential downside of 7.07%. Myriad Genetics has a consensus target price of $21.00, suggesting a potential downside of 22.02%. Given Alexion Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Alexion Pharmaceuticals is more favorable than Myriad Genetics.

Summary

Alexion Pharmaceuticals beats Myriad Genetics on 13 of the 15 factors compared between the two stocks.


Myriad Genetics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.92flat$147.24 billion$23.36 billion20.64Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.94flat$84.19 billion$22.45 billion67.98Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$220.35flat$56.78 billion$4.16 billion27.82Analyst Report
Analyst Revision
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$503.40flat$53.84 billion$7.86 billion18.40Analyst Report
Biogen logo
BIIB
Biogen
1.9$268.46flat$41.18 billion$14.38 billion8.89Upcoming Earnings
Analyst Report
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$165.17flat$36.16 billion$4.99 billion38.59News Coverage
Seagen logo
SGEN
Seagen
1.7$144.82flat$26.38 billion$916.71 million57.02Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$127.00flat$21.99 billion$876.29 million-57.47
Incyte logo
INCY
Incyte
1.7$82.72flat$18.18 billion$2.16 billion-52.69
Novavax logo
NVAX
Novavax
1.2$225.88flat$16.79 billion$18.66 million-43.27
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.55flat$16.29 billion$219.75 million-17.57
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.93flat$14.44 billion$1.70 billion18.29Analyst Report
News Coverage
Repligen logo
RGEN
Repligen
1.5$210.35flat$11.68 billion$270.24 million256.52Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.36flat$9.13 billion$788.10 million101.46Analyst Report
Increase in Short Interest
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$202.00flat$9.07 billion$1.45 billion19.11
Exelixis logo
EXEL
Exelixis
1.9$23.88flat$7.36 billion$967.78 million49.75Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$47.31flat$6.65 billion$195.99 million295.69
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$39.50flat$5.74 billion$1.12 billion82.29Analyst Report
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$68.41flat$4.16 billion$1.11 billion22.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.04flat$3.98 billion$806.43 million-9.21Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.54flat$3.25 billion$36.13 million-67.97
Alkermes logo
ALKS
Alkermes
1.2$20.11flat$3.16 billion$1.17 billion-43.72Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.18flat$2.91 billion$901.90 million-23.22
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.97flat$2.63 billion$182.24 million-8.67Analyst Upgrade
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.12flat$2.50 billion$120.28 million-148.61Unusual Options Activity
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.78flat$2.00 billionN/A-11.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.42flat$2.00 billion$48.83 million-15.03
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.69flat$1.71 billion$428.41 million15.49
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.40flat$1.65 billion$102.43 million-19.00Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$22.99flat$1.52 billion$68.46 million-65.69Analyst Report
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.33flat$1.50 billion$82.27 million-17.88
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$11.44flat$1.24 billion$35.22 million-8.35
Innoviva logo
INVA
Innoviva
1.4$11.82flat$1.21 billion$261.02 million6.03
Curis logo
CRIS
Curis
1.3$10.62flat$1.05 billion$10 million-12.95News Coverage
Gap Up
MannKind logo
MNKD
MannKind
1.4$4.20flat$1.04 billion$63.04 million-20.00Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$24.10flat$932.93 million$3.57 million-10.81
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.51flat$914.90 million$227.19 million45.86
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.93flat$812.29 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.95flat$728.99 million$322.07 million-4.71Upcoming Earnings
Decrease in Short Interest
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.23flat$716.63 million$150,000.00-4.61News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.24flat$669.56 million$252 million-2.07
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.87flat$625.09 million$143.01 million-1.12
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.45flat$609.03 million$59.29 million-23.00Increase in Short Interest
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.60flat$536.28 million$150.05 million-2.39
Geron logo
GERN
Geron
1.4$1.41flat$468.24 million$460,000.00-4.03Decrease in Short Interest
Gap Up
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.91flat$461.18 million$109.33 million-2.14
Verastem logo
VSTM
Verastem
1.3$2.71flat$460.07 million$17.46 million-1.92
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.45flat$455.14 million$22.27 million-4.14Analyst Revision
XOMA logo
XOMA
XOMA
1.5$36.35flat$422.18 million$18.37 million-32.75Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$3.97flat$391.02 million$36.63 million-4.67
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.